Deep Clinical Phenotyping of Parkinson’s Disease: Towards a New Era of Research and Clinical Care

Xu, Zhiheng; Shen, Bo; Tang, Yilin; Wu, Jianjun; Wang, Jian

doi:10.1007/s43657-022-00051-4

Cited by 5 publications

(3 citation statements)

References 177 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is evidence indicating that phenomic approach is a novel and revolutionary approach for accelerating profoundly the discoveries of novel risk factors (Andrews et al 2021 ; Nikpay and Mohammadzadeh 2020 ; Went et al 2020 ; Yang et al 2022 ; You et al 2022 ), diagnostic methods (Rahman and Rahman 2019 ; Viganò et al 2012 ; Xu et al 2022 ; Zhang et al 2021 , 2022a , e ), and therapeutic strategies (Delude 2015 ; Robinson 2012 ; Zhang et al 2021 ). Compared to genomic approach for studying diseases, phenomic studies on diseases determine a number of cross-scale phenomic parameters on several levels, including molecular level, cellular level, tissue and organ level, and systemic level (Table 1 ).…”

Section: Significance Of Phenomic Studies On Diseasesmentioning

confidence: 99%

“…To overcome these severe challenges, novel preventive strategies, diagnostic approaches and therapeutic strategies are urgently and critically needed. Increasing evidence has suggested that phenomics has provided a revolutionary strategy and approach for discovering new risk factors (Andrews et al 2021 ; Nikpay and Mohammadzadeh 2020 ; Went et al 2020 ; Yang et al 2022 ; You et al 2022 ), diagnostic biomarkers (Nicholson 2021 ; Xu et al 2022 ; Zhang et al 2022a ) and precision therapies (Delude 2015 ; Nicholson 2021 ; Robinson 2012 ; Zhang et al 2021 ) for human diseases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phenomic Studies on Diseases: Potential and Challenges

Ying

2023

Phenomics

View full text Add to dashboard Cite

The rapid development of such research field as multi-omics and artificial intelligence (AI) has made it possible to acquire and analyze the multi-dimensional big data of human phenomes. Increasing evidence has indicated that phenomics can provide a revolutionary strategy and approach for discovering new risk factors, diagnostic biomarkers and precision therapies of diseases, which holds profound advantages over conventional approaches for realizing precision medicine: first, the big data of patients' phenomes can provide remarkably richer information than that of the genomes; second, phenomic studies on diseases may expose the correlations among cross-scale and multi-dimensional phenomic parameters as well as the mechanisms underlying the correlations; and third, phenomics-based studies are big data-driven studies, which can significantly enhance the possibility and efficiency for generating novel discoveries. However, phenomic studies on human diseases are still in early developmental stage, which are facing multiple major challenges and tasks: first, there is significant deficiency in analytical and modeling approaches for analyzing the multi-dimensional data of human phenomes; second, it is crucial to establish universal standards for acquirement and management of phenomic data of patients; third, new methods and devices for acquirement of phenomic data of patients under clinical settings should be developed; fourth, it is of significance to establish the regulatory and ethical guidelines for phenomic studies on diseases; and fifth, it is important to develop effective international cooperation. It is expected that phenomic studies on diseases would profoundly and comprehensively enhance our capacity in prevention, diagnosis and treatment of diseases.

show abstract

Section: Significance Of Phenomic Studies On Diseasesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Phenomic Studies on Diseases: Potential and Challenges

Ying

2023

Phenomics

View full text Add to dashboard Cite

show abstract

“…Pathologically, PSP is the most common primary tauopathy (4-repeat form of tau), 13 and is clinically classified as an atypical parkinsonism syndrome that shares plenty of symptoms with Parkinson’s disease (PD) as well as other atypical parkinsonism syndromes like the parkinsonian subtype of multiple system atrophy (MSA-P), especially at early stages. 23 , 24 The significant phenotypic overlap and clinical heterogeneity make an early and accurate diagnosis of these conditions challenging. New-generation tau ligands with high affinity to both 3-repeat and 4-repeat forms of tau show promise in ameliorating this situation.…”

Section: Introductionmentioning

confidence: 99%